tbuckley/cabot-search huggingface dataset:
AB0710 Histological evaluation of enlarged submandibular glands in the diagnosis of systemic diseases
Authors: S. Sedyshev, V. Vasilyev, I. Gayduk, A. Kovrigina, O. Logvinenko, A. Borovskaya
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate the diagnostic of histological and immunomorphological studies of enlarged submandibular salivary glands (SSG) in the diagnosis of systemic diseases. <h3>Methods</h3> We examined 14 patients (male – 4, female - 10), mean age - 52.4 years (26 - 76) with unilateral or bilateral enlargement of SSG. All the patients were taken samples of SSG tissue. The applied techniques were extirpation of the SSG (n=8), incisional biopsy (n=3), needle biopsy (n=2), autopsy (n=1). In all cases histological and immunomorphological examination of SSG tissue. Eleven patients had xerostomia. Sialography showed parenchymal sialadenitis in 3 patients. Six patients had markers of autoimmune diseases (rheumatoid factor, antinuclear antibodies, anti-SSA, anti-SSB, ACCP, hypergammaglobulinemia), 4 – had signs of acute inflammation (CRP, elevated ESR). Histological study of enlarged submandibular salivary glands, especially when using a minimally invasive incisional biopsy, is a useful and informative method of diagnosing a wide range of systemic diseases. <h3>Results</h3> Most patients are sent for examination with suspected primary Sjögren's syndrome (n=6), sclerosing sialadenitis (n=4) or primary NHL (n=2). While the survey the initial diagnosis was withdrawn in 13 patients. On the basis of clinical, laboratory, histological and immunomorphological examination 6 patients were diagnosed with IgG4-RSD (Mikulicz's disease (n=2), Küttner's tumor (n=1), multifocal fibrosclerosos (n=2). In 7 cases various lymphoproliferative disease were diagnosed (MALT-lymphoma+rheumatoid arthritis (n=3), MALT-lymphoma+ pSS (n=1), primary AL-amyloidosis (n=2) and primary NHL (n=1). Generalized sarcoidosis was shown in 1 patient. <h3>Conclusions</h3> Histological study of enlarged submandibular salivary glands, especially when using a minimally invasive incisional biopsy, is a useful and informative method of diagnosing a wide range of systemic diseases. <h3>Disclosure of Interest</h3> None Declared
Differences in Rates of Gastrin Release in Normal Persons and Patients with Duodenal-Ulcer Disease
Authors: J. E. McGuigan, W. L. Trudeau
Journal: New England Journal of Medicine (1973)

To compare gastrin release in response to a physiologic stimulus in normal persons and in patients with duodenal-ulcer disease, serum gastrin levels were measured in 22 patients with duodenal ulcer and 10 control subjects before ingestion of a protein-rich meal (180 g of beef) and five 15-minute intervals thereafter. The mean fasting serum gastrin concentration for the 22 patients with duodenal ulcer (76 ± 7.0 S.E.M. pg per milliliter) did not differ from that of the control subjects (71 ± 9.4 pg per milliliter). However, mean serum gastrin concentrations in the patients with duodenal ulcer were significantly greater than those of the control subjects 45, 60, and 75 minutes after feeding. The integrated gastrin response to feeding in these patients (99 ± 25 per cent) substantially and significantly (p less than 0.01) exceeded that of the control population (44 ± 10 per cent). Thus, increased gastrin release occurs in response to feeding in such patients as compared with normal persons, and, in spite of the absence of fasting hypergastrinemia, indicates the potential importance of gastrin in the hypersecretory state that frequently characterizes duodenal-ulcer disease.
SAT0124 Follow -up of safety and long-term efficacy of etanercept in 1596 patients with active rheumatoid polyarthritis in belgium
Authors: C. Boone
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To describe the long-term efficacy and types of adverse events (AEs) in rheumatoid arthritis (RA) patients treated with etanercept in a daily clinical setting in Belgium. <h3>Methods</h3> A prospective, multi-center, open-label, observational study in patients with active RA, who have previously failed 2 disease-modifying anti-rheumatic drugs (DMARD's), one of which being methotrexate (MTX). Patients were treated with etanercept 25 mg subcutaneously twice a week or 50 mg OW, Health Assessment Questionnaire (HAQ-DI) was completed, swollen joint count was made, and adverse events (AEs) occurring during the previous period were registered. <h3>Results</h3> Demographics and disease characteristics of 1596 patients are listed in table 1. 1596 patients were treated with etanercept, representing a total of 4461 Patient-Years. Patients were followed for at least 1 year and a maximum of 5.5 years. 730 patients discontinued treatment. The main reason (out of 6) for discontinuation was non-response (primary and secondary, at the discretion of the treating physician) (n=276). The other 2 main reasons are safety (n=227) and loss to follow-up (n=95). 878 (56.87%) patients reported adverse events of which 788 events were related to the treatment. 246 (15.93%) patients reported a serious adverse event (death, life-threatening, hospitalization, persistent disability, congenital anomaly or birth defect, pregnancy, overdose, abuse or new malignancy) of which 226 events are considered to be related to the treatment. Safety outcomes are listed in Table 2. Infections were the most frequent AE's. Injection site reactions were uncommon (n=46). No cases of tuberculosis were reported. Efficacy was evaluated by measuring number of joints with active synovitis and HAQ-DI. At baseline, the mean number of joints with active synovitis was 15.1±7.6. At month 6, the mean number of joints with active synovitis decreased to 4.0±5.4. At month 78, the mean number of joints with synovitis further decreased to 1.6±2.7. This represents a statistically significant decrease at both time points from baseline. At baseline, the mean HAQ-DI-score (/60) was 31.2±9.5. At month 6, the mean HAQ- DI score decreased to 15.9±11.3. At month 78, the HAQ-DI-score was 10.4±9.4. This represents a statistically significant decrease at both time points from baseline. <h3>Conclusions</h3> This very first report with results from 1596 patients treated with etanercept in Belgium confirms the safety and efficacy profile in rheumatoid arthritis when used in daily clinical practice. No new safety signals were detected. <h3>Disclosure of Interest</h3> C. Boone Employee of: Pfizer
Making endoscopy mobile: a novel initiative for public healthcare
Authors: R. Talukdar, D. Nageshwar Reddy
Journal: Endoscopy (2012)

Public healthcare has progressed immensely in the past few decades. However, the rural masses in the developing and underdeveloped countries very often have limited access to the advanced healthcare technology. At the Asian Institute of Gastroenterology, Hyderabad, India, the Rural Health Care Project has been initiated in an attempt to provide cost-effective gastrointestinal care to the rural population. The Project was implemented by traveling to remote rural areas in a bus that had been converted into a mobile hospital and equipped with basic diagnostic facilities including a custom-made endoscopy unit. The mobile hospital and endoscopy unit is accompanied by a telemedicine vehicle that transmits all procedures and data to the main telemedicine center at the parent institute in Hyderabad. Our efforts have resulted in cost-effective management and robust data collection of several common gastrointestinal illnesses in remote rural areas of the Indian state of Andhra Pradesh. To date, 32756 endoscopic procedures have been carried out in a population of over 10 million people spanning 4837 villages. Overall, 72 % of the population has had a positive finding on upper gastrointestinal endoscopy (primarily related to acid peptic diseases). Interestingly, < 1 % of the population have had colonic polyps on screening colonoscopy, whereas the prevalence of infective colitis has been high. This whole exercise has produced a high level of satisfaction among both beneficiaries and care-givers; it has also offered doctors in training the opportunity to encounter and manage common public health-related problems. This program is funded by philanthropic donations.
CARDIAC INVOLVEMENT IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS
Authors: Mina Nakayama, Yukiko Morita, Megumi Yamamuro, Naoki Nakayama, Yuichi Okajima, Shinnosuke Kikuchi, Toru Dejima, Yoriko Horiguchi, Masahiko Kanna, Kazuo Kimura, Satoshi Umemura
Journal: Journal of the American College of Cardiology (2016)
A1.34 ACPA fine specificity is associated with increased plasmablast numbers and worse clinical response to rituximab in rheumatoid arthritis
Authors: E Vital, L Israelsson, L Nogueira, V Malmström, Yasser El-Sherbiny, AC Rawston, G Serre, L Klareskog, F Ponchel, P Emery
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Quality and duration of response to rituximab in RF/CCP-positive RA is variable. Higher pre-and post-treatment plasmablasts are associated with non/short-response. The objective of this study was to assess the relationship of ACPA fine specificity with clinical response and B cell subsets in RA patients treated with rituximab. <h3>Methods</h3> 82 patients with active RA received 2x1000mg rituximab. Clinical response was assessed using DAS28 and EULAR criteria at 0, 6 and 12 months. Presence of antibodies were analysed by ELISA as previously described. One hundred and fifty healthy controls were used to determine the 98th percentile for positivity. At 0 and 6 month we measured IgM-, IgG- and IgA-RF using commercial ELISAs (EuroImmun); anti-CCP2 using Phadia Immunocap; and antibodies against citrullinated Vimentin60-75(Vim60-75), alpha-enolase (CEP-1), collagen II(CII-C1, CII-U1), a collagen II peptide (CIICitC1), and peptides of the Fibrinogen alpha and beta chain (Fib-alpha, Fib-beta) using in-house assays in University of Toulouse and Karolinska Institute. B cell naïve (CD19<sup>+</sup> CD27-CD38-), memory (CD19<sup>+</sup> CD27<sup>+</sup> CD38-) and plasmablast (CD19<sup>+</sup>/-CD27<sup>++</sup> CD38<sup>++</sup>) subsets were enumerated by flow cytometry as previously described. <h3>Results</h3> Mean (SD) baseline DAS28 was 5.63(1.08). Presence of each RF isotype was associated with higher DAS28, but individual ACPA epitopes were not associated with baseline disease activity. EULAR Non/Moderate/Good responses at 6 months were 26/38/37% respectively. Clinical response was not related to IgM/G/A-RF status at baseline or change in titre. CCP2 was not associated with any clinical outcome. EULAR Non-responders had higher baseline titres of CIICitC1(p = 0.038), CEP-1(p = 0.088) and Fib beta-60-74(p = 0.093). There was a trend to lower Mod/Good response rate for patients positive for each specific ACPA epitope - this was significant only for Vim60-75 (61 vs. 84%, p = 0.031). However, the total number of positive epitopes at baseline was significantly higher in patients with EULAR Non response (median (IQR):4(2-5) vs. 2(1-4), p = 0.008). After a second cycle of rituximab, there was a further reduction in Vim60-75 (p = 0.043) and CEP-1 (p = 0.068), but not CCP (p = 0.382). Number of ACPA epitopes positive was associated with higher numbers of plasmablasts in early B cell repopulation at 6 months (Figure 1). <h3>Conclusions</h3> Here, for the first time, we associate clinical response and B cell repopulation pattern after rituximab with the presence of ACPA with particular fine specificity. These results suggest that specificity for ACPA epitopes rather than CCP2 is linked to the mechanism of action of B cell depletion in RA, and that plasmablasts in early repopulation are disease-associated.
Delineation of the Extent of Coronary Atherosclerosis by High-Frequency Epicardial Echocardiography
Authors: David D. McPherson, Loren F. Hiratzka, Wade C. Lamberth, Berkeley Brandt, Michelle Hunt, Robert A. Kieso, Melvin L. Marcus, Richard E. Kerber
Journal: New England Journal of Medicine (1987)

Postmortem studies suggest that coronary angiography does not always accurately delineate the extent of coronary-artery disease. We examined this problem in living human hearts by performing high-frequency epicardial echocardiography at the time of cardiac surgery. The ratio of the diameter of the lumen of the coronary artery to the thickness of its wall was used to quantify the severity of coronary lesions. In 11 patients with no angiographic evidence of coronary disease anywhere in the coronary tree, the mean (±SEM) ratio was 5.9±0.3. In 21 patients with angiographic disease at the site evaluated by echocardiography, the mean ratio was lower (2.3±0.2, P<0.05), reflecting encroachment into the arterial lumen by atherosclerotic plaque. In 15 patients with arterial segments that were angiographically normal but with arterial stenoses elsewhere in the coronary tree, the mean ratio was 4.1±0.3, with marked overlap with the values in the patients who had angiographic disease at the site of the echocardiographic evaluation. These results demonstrate, in living human hearts, that diffuse coronary atherosclerosis is often present when coronary angiography reveals only discrete stenoses. This finding suggests that coronary angiography may underestimate the severity and extent of coronary disease. (N Engl J Med 1987; 316:304–9.)
AB0432 Overlapping neuropsychiatric manifestations in patients with systemic lupus erythematosus
Authors: S. V. Monov, R. K. Rashkov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a systemic disease of the connective tissue that is characterized bydamages of all organs and systems. Lesions of the nervous system in relation to the underlying disease vary widely depending on the methods used for their detection. In 1999 the ACRAdHocCommitteeofNeuropsychiatricLupusNomenclaturehas defined19possible damagestothe nervous system in SLE patients (pts). <h3>Objectives</h3> To identifythe most common variants of overlapping neuropsychiatric manifestations in pts with SLE. <h3>Methods</h3> 162 pts with SLE were monitored and assessed. Depending on the characteristics of the clinical course of SLE the pts were divided intotwo groups. Group I included 104 pts with clinically manifested disorders of the nervous system, while Group IIincluded 58ptswith incomplete SLE. In both groups multiple methods for diagnosis and detection of neuropsychiatricdamages were used. <h3>Results</h3> Overlapping neuropsychiatric manifestations were observed in 93 (89.42%) pts with clinically manifested damages to the nervous system and in 24 pts (41.38%) with incomplete SLE. In both groups cognitive and autonomous disorders mostly overlapped the other neuropsychiatric manifestations. <h3>Conclusions</h3> The types ofoverlapping neuropsychiatric manifestations in pts with SLE and incompleteSLE are various. Studying the overlap of these manifestations in SLE pts may help for optimizing the therapeutic strategies. <h3>Disclosure of Interest</h3> None Declared
Progress in endoscopy: areas of current interest and topics to watch out for
Authors: T. Rösch
Journal: Endoscopy (2012)

The past few years have seen a shift in focus for endoscopy research. For example, there has been a halt in the apparent revolution of natural orifice transluminal surgery (NOTES), which was long considered the most important innovation in flexible endoscopy. Other trends such as endoscopic histology are slowing down and not progressing into clinical practice. In general, the quality of endoscopic research needs to be improved, particularly in the field of diagnostics and imaging <xref idref="JR682-1">1</xref>. Nevertheless, progress in some areas continues, albeit at a slower pace than we might like. In this review the areas of current interest are reviewed with reference to the most relevant areas of progress in recent years.
The Effectiveness of the Varicella Vaccine in Clinical Practice
Authors: Marietta Vázquez, Phillip S. LaRussa, Anne A. Gershon, Sharon P. Steinberg, Kimberly Freudigman, Eugene D. Shapiro
Journal: New England Journal of Medicine (2001)

A live attenuated varicella vaccine was approved for use in the United States in March 1995 and is recommended for all susceptible persons 12 months of age or older.To assess the effectiveness of the varicella vaccine, we conducted a case-control study with two controls per child with chickenpox, matched according to both age and pediatric practice. Children with potential cases of chickenpox were identified by active surveillance of pediatric practices in the New Haven, Connecticut, area. Research assistants visited the children on day 3, 4, or 5 of the illness, assessed the severity of the illness, and collected samples from lesions to test for varicella-zoster virus by polymerase chain reaction (PCR).From March 1997 through November 2000, data collection was completed for 330 potential cases, of which 243 (74 percent) were in children who had positive PCR tests for varicella-zoster virus. Of the 56 vaccinated children with chickenpox, 86 percent had mild disease, whereas only 48 percent of the 187 unvaccinated children with chickenpox had mild disease (P<0.001). Among the 202 children with PCR-confirmed varicella-zoster virus and their 389 matched controls, 23 percent of the children with chickenpox and 61 percent of the matched controls had received the vaccine (vaccine effectiveness, 85 percent; 95 percent confidence interval, 78 to 90 percent; P<0.001). Against moderately severe and severe disease the vaccine was 97 percent effective (95 percent confidence interval, 93 to 99 percent). The effectiveness of the vaccine was virtually unchanged (87 percent) after adjustment for potential confounders by means of conditional logistic regression.Varicella vaccine is highly effective as used in clinical practice.
Obstetrical Nursing. A Manual For Nurses and Students and Practitioners of Medicine.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1829: Negative regulation of lncRNA GAS5 by miR-21.
Authors: Ziqiang Zhang, Yin-yuan Mo
Journal: Cancer Research (2013)

Abstract Protein-coding genes account for only a small part of the human genome whereas the vast majority of transcripts make up the non-coding RNAs including microRNAs and long non-coding RNAs (lncRNAs). Both microRNAs and lncRNAs have been shown to play a critical role in regulation of cellular processes such as cell growth and apoptosis as well as cancer progression and metastasis. As master gene regulators, microRNAs can target a large number of protein-coding genes. However, it remains to be determined whether microRNAs can also target lncRNAs. In the present study, we determined whether miR-21 impacts lncRNA expression. Using lncRNA RT-PCR array carrying 83 human disease related lncRNAs, we showed that miR-21 was capable of repressing the growth arrest specific 5 (GAS5) lncRNA which was previously shown to be involved in growth arrest. This negative regulation between miR-21 and GAS5 was confirmed in breast tumor specimens. Of interest, GAS5 can also repress miR-21 expression. While ectopic expression of GAS5 suppressed, GAS5 siRNAs increased miR-21 expression. Importantly, there was a putative miR-21 binding site in exon 5 of GAS5; deletion of the miR-21 binding site abolished this activity. We further showed that biotin labeled GAS5 RNA probe was able to pull down the RNA-induced silencing complex (RISC) and subsequently identified miR-21 in this GAS5-RISC complex, implying that miR-21 and GAS5 may regulate each other in a way similar to the microRNA-mediated silencing of target mRNAs. Together, these results support the “endogenous competitive RNA” concept that microRNAs may regulate not only protein-coding genes, but also non-coding genes such as GAS5. Citation Format: Ziqiang Zhang, Yin-yuan Mo. Negative regulation of lncRNA GAS5 by miR-21. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1829. doi:10.1158/1538-7445.AM2013-1829
CB-13 * PHENOTYPIC CHANGES BY NUCLEAR-ENCODED CYTOCHROME C OXIDASE SUB-UNIT 4, ISOFORM 1 SUPPORTS POOR PROGNOSTIC IN GBM PATIENTS
Authors: C. Oliva, N. Reeve, T. Markert, C. E. Griguer
Journal: Neuro-Oncology (2014)

Cytochrome c Oxidase is a mitochondrial enzyme involved in cellular respiration and production of energy. Previously, we demonstrates that a high enzymaticl activity is associated with poor overall survival in GBM patients () and chemoresistance to Temozolomide. Thus, we hypothesize that CcO may be directly involved in the aggressive phenotype of these tumors. Elevated CcO activity is associated with a switch in CcO subunit 4. We use gene targeting of CcO sub-unit 4 isoform 1 or 2 (COX4i1 and COX4i2) and patient xenoline tumors. Genetic swap between COX4i2 and COX4i1 significantly increased tumor growth and proliferation in vitro and in vivo. However, under hypoxic condition, COX4i1 cells stopped proliferating and became more invasive. Our results support the view that COX subunit 4-1 drives tumor cell growth, proliferation and invasion. Moreover, manipulation of COX4 isoforms uncoupled cell proliferation from cell invasion; this control is hypoxia –dependent. This result provides evidence for a novel role for CcO beside its mitochondrial function. Supported by P20 CA151129-02 (NCI SPORE Program) and R01 CA160821 (USPHS/NIH/NCI)